Natera, Inc. (NASDAQ:NTRA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. The US$15b market-cap company posted a loss in its most recent financial year of US$435m and a latest trailing-twelve-month loss of US$292m shrinking the gap between loss and breakeven. As path to profitability is the topic on Natera's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

See our latest analysis for Natera

Consensus from 18 of the American Biotechs analysts is that Natera is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$14m in 2026. So, the company is predicted to breakeven approximately 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 71% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Natera's growth isn’t the focus of this broad overview, but, keep in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one issue worth mentioning. Natera currently has a relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in Natera's case is 44%. A higher level of debt requires more stringent capital management which increases the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Natera, so if you are interested in understanding the company at a deeper level, take a look at Natera's company page on Simply Wall St. We've also compiled a list of relevant factors you should look at:

1. Valuation: What is Natera worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Natera is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Natera’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.